The world’s first personalised mRNA cancer jab for melanoma has cut the risk of patients dying or cancer returning by 42% when combined with immunotherapy, a large trial shows.
The drug, which was given to patients in the UK and worldwide, is also being tested in other cancers, including kidney, bladder and lung cancer.
